{"id":30719,"date":"2024-06-13T13:39:47","date_gmt":"2024-06-13T13:39:47","guid":{"rendered":"https:\/\/leyton.com\/ca\/?post_type=news&p=30719"},"modified":"2025-05-23T17:40:32","modified_gmt":"2025-05-23T17:40:32","slug":"leyton-x-bioquebec","status":"publish","type":"news","link":"https:\/\/leyton.com\/ca\/en\/news\/leyton-x-bioquebec\/","title":{"rendered":"LEYTON x BIOQUEBEC"},"content":{"rendered":"\n

On May 30<\/strong>, 2024, from 8:00 am to 11:30 am, we had the pleasure of organizing a joint event with BioQu\u00e9bec<\/strong>. For the occasion, we welcomed a prestigious discussion panel featuring Benoit Larose<\/a>, CEO of BioQu\u00e9bec, V\u00e9ronique Dugas<\/a>, Vice-President of CQDM, Claude Leduc<\/a>, CEO of RNA Technologies and Yvan C\u00f4t\u00e9<\/a>, CEO of Neopharm.<\/p>\n\n\n\n

Laurent Lecanu<\/a>, Director of Business Development, Pharma Division, was also on hand to lead the discussion on the strategic use of non-dilutive financial levers available in Quebec and Canada to grow and anchor life sciences companies in Quebec<\/strong>.<\/p>\n\n\n\n

The questions posed by the audience gave rise to very constructive and fruitful discussions: from concerns about the difficulty of navigating the murky waters of funding opportunities, to the absence of a program that would fund 100% of a given project, to the evolution of the SR&ED program<\/a>.<\/p>\n\n\n\n

Concluding remarks underlined the need for biotech\/pharmaceutical\/medical companies to make IP strategy and use the SR&ED Tax Credit Program a top priority. And despite the obstacles identified, the multiplicity and depth of funding programs, Quebec is both a unique and attractive location.<\/p>\n\n\n\n

To illustrate this, Laurent Lecanu posed the following question: \u201cI know the answer, but I have to ask if there’s reason to be optimistic about the life sciences industry in Quebec\u201d<\/strong>.<\/p>\n\n\n\n

The panelists unanimously answered \u201cYes\u201d. Like them, he shares this opinion: “Quebec has all the resources – human, scientific, manufacturing and logistical – to become a major player in innovation and a key partner in the international life sciences sector. If you are developing an R&D project in the life sciences sector, contact our experts to find out which programs are eligible for your company.<\/strong>“<\/p>\n\n\n\n

<\/div>\n\n\n\n

Don’t wait to join our next Leyton events<\/strong>! Subscribe to our newsletter to receive our exclusive news.<\/p>\n\n\n\n

\n
\n

<\/p>

    <\/ul><\/div>\n
    \n
    \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/div>\n
    \n
    \n
    \n
    \n
    \n
    \n